CA3120383A1 - Composes et procedes d'utilisation associes pour le traitement du cancer - Google Patents

Composes et procedes d'utilisation associes pour le traitement du cancer Download PDF

Info

Publication number
CA3120383A1
CA3120383A1 CA3120383A CA3120383A CA3120383A1 CA 3120383 A1 CA3120383 A1 CA 3120383A1 CA 3120383 A CA3120383 A CA 3120383A CA 3120383 A CA3120383 A CA 3120383A CA 3120383 A1 CA3120383 A1 CA 3120383A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
heteroaryl
heterocyclyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3120383A
Other languages
English (en)
Inventor
Liansheng Li
Yuan Liu
Tao Wu
Pingda Ren
Yi Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Araxes Pharma LLC
Original Assignee
Araxes Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araxes Pharma LLC filed Critical Araxes Pharma LLC
Publication of CA3120383A1 publication Critical patent/CA3120383A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés présentant une activité en tant qu'inhibiteurs de la protéine KRAS portant la mutation G12C. Les composés ont la structure suivante (I) : (I) ou un sel pharmaceutiquement acceptable, un stéréoisomère, une forme isotopique ou un promédicament de ceux-ci, A, B, R1, R3, L1, L2, L3, E, A1, A2, A3, A4, G1, G2,W, X, Y, Z, m1, m2, n1 et n2 étant tels que définis dans la description. L'invention concerne en outre des procédés associés à la préparation et à l'utilisation desdits composés, des compositions pharmaceutiques comprenant ces composés et des procédés de modulation de l'activité de la protéine KRAS portant la mutation G12C pour le traitement de troubles, tels que le cancer.
CA3120383A 2018-11-29 2019-11-27 Composes et procedes d'utilisation associes pour le traitement du cancer Pending CA3120383A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862773104P 2018-11-29 2018-11-29
US201862773084P 2018-11-29 2018-11-29
US62/773,104 2018-11-29
US62/773,084 2018-11-29
PCT/US2019/063702 WO2020113071A1 (fr) 2018-11-29 2019-11-27 Composés et procédés d'utilisation associés pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CA3120383A1 true CA3120383A1 (fr) 2020-06-04

Family

ID=68966062

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3120383A Pending CA3120383A1 (fr) 2018-11-29 2019-11-27 Composes et procedes d'utilisation associes pour le traitement du cancer

Country Status (10)

Country Link
US (1) US20220112192A1 (fr)
EP (1) EP3887373A1 (fr)
JP (1) JP2022509830A (fr)
KR (1) KR20210097715A (fr)
CN (1) CN113227092A (fr)
AU (1) AU2019388998A1 (fr)
BR (1) BR112021010454A2 (fr)
CA (1) CA3120383A1 (fr)
MX (1) MX2021005924A (fr)
WO (1) WO2020113071A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
WO2017058728A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
EP3573970A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer
WO2018140512A1 (fr) 2017-01-26 2018-08-02 Araxes Pharma Llc Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
EP3630747A1 (fr) 2017-05-25 2020-04-08 Araxes Pharma LLC Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants
JP7451419B2 (ja) 2018-10-26 2024-03-18 大鵬薬品工業株式会社 新規なインダゾール化合物又はその塩
AU2019395338A1 (en) 2018-12-10 2021-07-29 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
CN112110918B (zh) * 2019-06-21 2023-08-22 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
CN110256421A (zh) * 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
IL292438A (en) 2019-10-28 2022-06-01 Merck Sharp & Dohme Small molecules that inhibit the g12c mutant of kras
WO2021108683A1 (fr) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
JP2023508482A (ja) * 2019-12-27 2023-03-02 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド スピロ環含有キナゾリン化合物
JP2023519815A (ja) * 2020-03-25 2023-05-15 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド スピロ環含有キナゾリン化合物
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
US20230357233A1 (en) * 2020-08-26 2023-11-09 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof
WO2022060583A1 (fr) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Utilisation d'inhibiteurs de sos1 pour traiter des malignités à mutations de shp2
WO2022063297A1 (fr) * 2020-09-27 2022-03-31 微境生物医药科技(上海)有限公司 Dérivé de quinazoline, son procédé de préparation et son utilisation
EP4223761A1 (fr) * 2020-09-30 2023-08-09 Shanghai Pharmaceuticals Holding Co., Ltd. Composé quinazoline et son application
MX2023004518A (es) * 2020-10-20 2023-06-19 Amgen Inc Compuestos espiro heterocíclicos y métodos de uso.
WO2022083616A1 (fr) * 2020-10-21 2022-04-28 贝达药业股份有限公司 Composé quinazoline et composition pharmaceutique associée
MX2023004802A (es) * 2020-10-27 2023-06-22 Amgen Inc Compuestos espiro heterocíclicos y métodos de uso.
TW202241869A (zh) * 2020-12-22 2022-11-01 大陸商上海科州藥物研發有限公司 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
CN117177744A (zh) 2021-01-29 2023-12-05 塞迪拉治疗股份有限公司 Cdk2抑制剂及其使用方法
CA3207800A1 (fr) * 2021-02-09 2022-08-18 Yang Zhang Composes cycliques aromatiques de pyrimidine
CN116783194A (zh) * 2021-02-09 2023-09-19 微境生物医药科技(上海)有限公司 含螺环的喹唑啉衍生物
CN117813306A (zh) * 2021-05-22 2024-04-02 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物，及其制备和治疗用途
WO2022266206A1 (fr) 2021-06-16 2022-12-22 Erasca, Inc. Conjugués d'inhibiteurs de kras
CN117561058A (zh) 2021-06-26 2024-02-13 塞迪拉治疗股份有限公司 Cdk2抑制剂及其使用方法
WO2023031781A1 (fr) 2021-09-01 2023-03-09 Novartis Ag Combinaisons pharmaceutiques comprenant un inhibiteur de tead et leurs utilisations pour le traitement de cancers
WO2023141300A1 (fr) * 2022-01-20 2023-07-27 Kumquat Biosciences Inc. Composés hétérocycliques et leurs utilisations
WO2024031088A1 (fr) 2022-08-05 2024-02-08 Kumquat Biosciences Inc. Composés hétérocycliques et leurs utilisations
CN117624170A (zh) * 2022-08-24 2024-03-01 泰励生物科技（上海）有限公司 具有抗kras突变肿瘤活性的化合物
WO2024206858A1 (fr) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
ES2183905T3 (es) 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0923585B1 (fr) 1996-07-18 2002-05-08 Pfizer Inc. Composes a base de phosphinate inhibiteurs des metalloproteases matricielles
CN1228083A (zh) 1996-08-23 1999-09-08 美国辉瑞有限公司 芳基磺酰氨基异羟肟酸衍生物
WO1998030566A1 (fr) 1997-01-06 1998-07-16 Pfizer Inc. Derives de sulfone cyclique
NZ336840A (en) 1997-02-03 2001-01-26 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
IL131123A0 (en) 1997-02-11 2001-01-28 Pfizer Arylsulfonyl hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
KR20160076519A (ko) 2013-10-10 2016-06-30 아락세스 파마 엘엘씨 Kras g12c 억제제
CN107849022A (zh) * 2015-04-10 2018-03-27 亚瑞克西斯制药公司 取代的喹唑啉化合物和其使用方法
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
WO2019213516A1 (fr) * 2018-05-04 2019-11-07 Amgen Inc. Inhibiteurs de kras g12c et leurs procédés d'utilisation
AU2020214032A1 (en) * 2019-01-29 2021-08-19 Brightgene Bio-Medical Technology Co., Ltd. Benzopyridone heterocyclic compound and use thereof
CN110256421A (zh) * 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂

Also Published As

Publication number Publication date
CN113227092A (zh) 2021-08-06
EP3887373A1 (fr) 2021-10-06
US20220112192A1 (en) 2022-04-14
AU2019388998A1 (en) 2021-06-03
BR112021010454A2 (pt) 2021-08-24
KR20210097715A (ko) 2021-08-09
WO2020113071A1 (fr) 2020-06-04
MX2021005924A (es) 2021-06-30
JP2022509830A (ja) 2022-01-24

Similar Documents

Publication Publication Date Title
US11377441B2 (en) Covalent inhibitors of KRAS
CA3120383A1 (fr) Composes et procedes d'utilisation associes pour le traitement du cancer
US10723738B2 (en) Inhibitors of KRAS G12C mutant proteins
US11639346B2 (en) Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
EP3283462B1 (fr) Inhibiteurs tricycliques condensés de kras et procédés pour les utiliser
AU2016355433B2 (en) 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US10975071B2 (en) Inhibitors of KRAS G12C mutant proteins
US10144724B2 (en) Substituted quinazoline compounds and methods of use thereof
AU2019364417A1 (en) 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of G12C mutant KRAS protein for inhibiting tumor metastasis
EP3829580A1 (fr) Composés hétérocycliques spiro et procédés d'utilisation correspondants pour le traitement du cancer
EP3630746A1 (fr) Composés et leurs procédés d'utilisation pour le traitement du cancer
CA2993013A1 (fr) Composes de quinazoline substitues et leur utilisation en tant qu'inhibiteurs de proteines kras, hras et/ou nras mutantes g12c